stock price

Of the 28 companies in the index, 21 firms saw their stock prices increase throughout the first half of the year, while seven firms' share prices decreased.

Of the 28 companies in the index, 18 firms saw their stock prices increase, while 10 firms' share prices decreased. 

Celcuity's companion diagnostic platform CELsignia identifies cellular signals corresponding to drug response using a patient's living tumor cells.

Of the 28 companies in the index, 27 firms saw their stock prices increase, while one firm's share price decreased slightly.

The San Diego-based genome mapping firm's share price fell below $1.00 for 30 consecutive days, triggering a noncompliance notification from Nasdaq.

The genome mapping firm had fallen out of compliance with respect to its loan agreement with Innovatus and will prepay $5 million toward the loan principal.

Of the 28 companies in the index, nine companies' share prices increased while the share values of 19 declined month over month.  

The company's Q4 revenues exceeded Wall Street estimates and the clinical genetic testing and pharma services businesses outperformed expectations. 

Of the 28 companies in the index, 16 companies' share prices increased while the share values of 12 declined month over month. 

The company's Lyo-Ready 1-Step RT-qPCR mix is being used by diagnostic labs in China to develop screening assays for the virus.